Pablo Rendo Selected Research

Anemia

1/2002

[Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pablo Rendo Research Topics

Disease

7	Hemorrhage 05/2021 - 10/2013
6	Hemophilia A (Haemophilia) 01/2024 - 10/2013
5	Hemophilia B (Haemophilia B) 05/2021 - 12/2015
1	Body Weight (Weight, Body) 10/2013
1	Inflammation (Inflammations) 10/2013
1	Joint Diseases (Joint Disease) 10/2013
1	Anemia 01/2002
1	Neoplasms (Cancer) 01/2002
1	Infections 01/2002

Drug/Important Bio-Agent (IBA)

6	Factor IX (Coagulation Factor IX)FDA LinkGeneric 05/2021 - 10/2013
4	recombinant factor VIII SQIBA 09/2020 - 10/2015
4	Factor VIII (Coagulation Factor VIII)IBA 01/2020 - 10/2013
3	AlbuminsIBA 01/2020 - 10/2015
2	Therapeutic UsesIBA 10/2015 - 01/2002
1	factor VIII-Fc fusion proteinIBA 01/2024
1	prothrombin complex concentrates (PPSB)IBA 01/2018
1	fibrin fragment D (D-dimer)IBA 01/2018
1	Prothrombin (Factor II)IBA 01/2018
1	antithrombin III-protease complexIBA 01/2018
1	Hemostatics (Antihemorrhagics)IBA 10/2013
1	Erythropoietin FDA Link 01/2002
1	Alanine Transaminase (SGPT)IBA 01/2002

Therapy/Procedure

2	Therapeutics 05/2021 - 01/2018
1	Renal Dialysis (Hemodialysis) 01/2002